A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP
© 2019 Latin Clinical Trial Center.
All Rights Reserved.
Powered By Millennial Networks